Pith. sign in

REVIEW

Characterization of a modified clinical linear accelerator for ultra-high dose rate electron beam delivery

Not yet reviewed by Pith; the record is open.

This paper has not been read by Pith yet. Machine review is queued; the pith claim, tier, and objections will appear here once it completes.

SPECIMEN: schema-true, not a live event

T0 review · schema-true

One-sentence machine reading of the paper's core claim.

pith:XXXXXXXX · record.json · timestamp

arxiv 2407.16027 v1 pith:243GDHC7 submitted 2024-07-22 physics.med-ph

Characterization of a modified clinical linear accelerator for ultra-high dose rate electron beam delivery

classification physics.med-ph
keywords dosebeamrateelectronpulseuhdracceleratoraverage
verification ladder T0 review T1 audit T2 compute T3 formal T4 reserved
0 comments
read the original abstract

Irradiations at Ultra High Dose Rate (UHDR) regimes, exceeding 40 Gy/s in single fractions lasting less than 200 ms, have shown an equivalent antitumor effect compared to conventional radio-therapy with reduced harm to normal tissues. This work details the hardware and software modi-fications implemented to deliver 10 MeV UHDR electron beams with a Linear Accelerator Elekta SL 18 MV and the beam characteristics obtained. GafChromic EBT XD films and an Advanced Markus chamber were used for the dosimetry characterization, while a silicon sensor assessed the machine's beam pulses stability and repeatability. Dose per pulse, average dose rate and instantaneous dose rate in the pulse were evaluated for four experimental settings, varying the source-to-surface dis-tance and the beam collimation, i.e. with and without the use of a cylindrical applicator. Results showed dose per pulse from 0.6 Gy to a few tens of Gy and average dose rate up to 300 Gy/s. The obtained results demonstrate the possibility to perform in-vitro radiobiology experiments and test of new technologies for beam monitoring and dosimetry at the upgraded LINAC, thus contributing to the electron UHDR research field.

discussion (0)

Sign in with ORCID, Apple, or X to comment. Anyone can read and Pith papers without signing in.